NasdaqHealth CareHealth Care SuppliesS&P SmallCap 600
$10.70
-2.14 (-16.67%)
Close of Nov 06, 2026 · end-of-day data
QDEL 8-K filings in 2025
Every material Form 8-K QuidelOrtho filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
QuidelOrtho reported third-quarter 2025 results with revenue of $700 million, down 4% from $727 million a year earlier, mainly due to lower COVID-19 and Donor Screening revenue. A $701 million non-cash goodwill impairment charge drove a GAAP net loss of $733 million, while adjusted diluted EPS was $0.80 versus $0.85 and adjusted EBITDA rose to $177 million from $171 million. The company narrowed its full-year 2025 revenue and adjusted EBITDA guidance ranges and updated adjusted EPS guidance to $2.00 to $2.15 to reflect its debt refinancing.
Q3 2025 total revenue was $700 million, down 4% as reported; non-respiratory revenue rose 5% as reported
GAAP diluted loss per share was $10.78 versus a $0.30 loss a year earlier, including a $701 million goodwill impairment charge
Adjusted EBITDA was $177 million, a 25% margin, compared with $171 million and 23% a year earlier
Full-year 2025 guidance: revenue $2.68 to $2.74 billion, adjusted EBITDA $585 to $605 million, adjusted diluted EPS $2.00 to $2.15
QuidelOrtho entered a credit agreement with Bank of America as administrative agent that provides $1.15 billion and $1.45 billion term loans, a $100 million delayed draw term loan and a $700 million revolver. The company borrowed the full Term Loan A and Term Loan B amounts on August 21, 2025 and used the proceeds, plus cash on hand, to repay its 2022 credit agreement. The company says the refinancing extends debt maturities and reduces required amortization payments.
Term Loan A of $1.15 billion matures August 21, 2030; Term Loan B of $1.45 billion matures August 21, 2032
Initial rate on Term Loan B is 4.00% per annum for Term SOFR loans; Term Loan A and revolver start at 2.25% per annum for Term SOFR loans
Financial covenants include a maximum Consolidated Leverage Ratio of 4.50 to 1.00 for the first three years, then 4.25 to 1.00, and a minimum Consolidated Interest Coverage Ratio of 3.00 to 1.00
Loans are secured by substantially all assets of the company and guarantor subsidiaries, excluding real property and certain other excluded assets
QuidelOrtho reported second-quarter 2025 revenue of $614 million, down from $637 million a year earlier, and a GAAP net loss of $255 million, or $3.77 per diluted share, versus a $148 million loss in the prior-year quarter. The loss includes $179 million in mostly non-cash restructuring, integration and other charges, while adjusted diluted EPS rose to $0.12 from a loss of $0.07 and adjusted EBITDA rose to $107 million from $90 million. The company reiterated its full-year 2025 guidance.
Total revenue was $614 million versus $637 million, down about 4%, mainly due to lower COVID-19 and Donor Screening revenue.
GAAP diluted loss per share was $3.77 versus $2.20 a year earlier; GAAP net loss was $255 million.
Adjusted diluted EPS was $0.12 versus a loss of $0.07; adjusted EBITDA margin was 17%, a 330 basis point improvement.
Full-year 2025 guidance was reiterated, including total revenue of $2.60 to $2.81 billion and adjusted diluted EPS of $2.07 to $2.57.
At its annual meeting, QuidelOrtho stockholders approved an amended and restated 2018 Equity Incentive Plan that adds 6,200,000 shares for issuance and extends the plan's term to May 20, 2035. Stockholders also elected all eleven director nominees and ratified KPMG LLP as the independent auditor for fiscal 2025. The filing reports routine annual meeting votes and does not report a change in financial results.
Equity plan amended to authorize 6,200,000 additional shares of common stock, with the term extended to May 20, 2035
Plan approval vote: 56,197,594 for, 3,246,510 against, 16,694 abstentions, and 3,395,934 broker non-votes
All eleven director nominees were elected; Kenneth J. Widder, M.D. received 58,150,438 votes for and Kenneth F. Buechler, Ph.D. received 56,977,744
KPMG LLP ratified as independent registered public accounting firm for fiscal 2025 with 62,737,831 votes for
QuidelOrtho reported first-quarter 2025 revenue of $693 million, down from $711 million a year earlier, mainly due to lower COVID-19 and Donor Screening sales. Adjusted diluted EPS rose to $0.74 from $0.44, and GAAP net loss narrowed to $13 million from $1.71 billion, which included a prior-year goodwill impairment charge. The company maintained its full-year 2025 guidance, so shareholders see weaker sales offset by higher profitability.
Total revenue was $693 million versus $711 million a year earlier; non-respiratory revenue was flat at $573 million.
Adjusted diluted EPS was $0.74, compared with $0.44 in the prior-year period; adjusted EBITDA was $160 million versus $132 million.
GAAP net loss was $13 million, compared with $1.71 billion a year earlier, which included a $1.74 billion goodwill impairment charge.
Full-year 2025 guidance was maintained, including reported revenue of $2.60 to $2.81 billion and adjusted diluted EPS of $2.07 to $2.57.
QuidelOrtho reported fourth-quarter 2024 revenue of $708 million, down from $743 million, and a GAAP net loss of $153 million. For the full year, revenue fell to $2.78 billion from $3.00 billion, and the net loss was $2.03 billion, driven by a $1.82 billion goodwill impairment charge. The company also issued 2025 guidance of $2.60 billion to $2.81 billion in revenue and $575 million to $615 million in adjusted EBITDA.
Q4 2024 revenue was $708 million versus $743 million; GAAP diluted loss was $2.28 per share versus earnings of $0.10 per share
Full-year 2024 GAAP diluted loss was $30.16 per share, including a goodwill impairment charge of approximately $1.82 billion
Full-year 2024 adjusted diluted EPS was $1.85, down from $4.13; adjusted EBITDA was $543 million versus $723 million
2025 guidance: total revenue $2.60 billion to $2.81 billion, adjusted EBITDA $575 million to $615 million, adjusted diluted EPS $2.07 to $2.57
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every QuidelOrtho filing is on SEC EDGAR ↗. 8-K briefs of other companies →